Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative propranolol and celecoxib for stage III melanoma surgery
ACTRN12624001353583Phase 2Withdrawn
- Sponsor
- Sydney Local Health District
- Start
- Jun 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of propranolol and celecoxib in melanoma (2 arms), sponsored by Sydney Local Health District. Primary endpoint: Change in tumor immune and proliferative markers. Planned start Jun 2025; status: withdrawn.
02
Drugs
propranololcelecoxib
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12624001353583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001353583.